[1] Corti O,Hampe C,Darios F,et al. Parkinson's disease: from causes to mechanisms[J]. C R Biol,2005,328(2):131-142. [2] Gerlach M,Riederer P and Scheller D. Mechanisms underlying and medical management of L-Dopa-associated motor complications[J]. J Neural Transm,2011,118(12):1659-1660. [3] Pinder R M. Drugs for Parkinson's disease: levodopa is still the gold standard[J]. Neuropsychiatr Dis Treat,2008,4(1):i-ii. [4] Poewe W,Antonini A,Zijlmans J C,et al. Levodopa in the treatment of Parkinson's disease: an old drug still going strong[J]. Clin Interv Aging,2010,5:229-238. [5] Calabresi P,Di Filippo M,Ghiglieri V,et al. Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap[J]. Lancet Neurol,2010,9(11):1106-1117. [6] Jenner P. Molecular mechanisms of L-DOPA-induced dyskinesia[J]. Nat Rev Neurosci,2008,9(9):665-677. [7] Murata M. Pharmacokinetics of L-dopa[J]. J Neurol,2006,253(3 Suppl):Ⅲ47-Ⅲ52. [8] Cai X Y,Kong X M,Fang Q,et al. An autoradiographic study on the pathogenesis of levodopa-induced dyskinesia: regulation of dopamine transporter by levodopa in a rat model of Parkinson's disease[J]. Neurodegener Dis,2012,9(1):11-17. [9] Matsumoto L,Takuma H,Tamaoka A,et al. CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson's disease[J]. PLoS One,2010,5(11):e15522. [10] Bottiglieri T,Arning E,Wasek B,et al. Acute administration of L-DOPA induces changes in methylation metabolites, reduced protein phosphatase 2A methylation, and hyperphosphorylation of Tau protein in mouse brain[J]. J Neurosci,2012,32(27):9173-9181. [11] Cenci M A,Lundblad M. Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia[J]. J Neurochem,2006,99(2):381-392. [12] Huot P,Johnston T H,Koprich J B,et al. L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease[J]. Neuropharmacology,2012,63(5):829-836. [13] Dethy S,Laute M A,Van Blercom N,et al. Microdialysis-HPLC for plasma levodopa and metabolites monitoring in parkinsonian patients[J]. Clin Chem,1997,43(5):740-744. [14] Hauser R A,Ellenbogen A L,Metman L V,et al. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease[J]. Mov Disord,2011,26(12):2246-2252. [15] Ogasahara S,Nishikawa Y,Takahashi M,et al. Dopamine metabolism in the central nervous system after discontinuation of L-dopa therapy in patients with Parkinson disease[J]. J Neurol Sci,1984,66(2-3):151-163. [16] Wijermans P,Lubbert M,Verhoef G,et al. Low-dose 5-aza-2,-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients[J]. J Clin Oncol,2000,18(5):956-962. [17] Ehrlich M. DNA methylation in cancer: too much, but also too little[J]. Oncogene,2002,21(35):5400-5413. [18] Tycko B. Epigenetic gene silencing in cancer[J]. J Clin Invest,2000,105(4):401-407. [19] Herman J G,Baylin S B. Gene silencing in cancer in association with promoter hypermethylation[J]. N Engl J Med,2003,349(21):2042-2054. |